<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35741698</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4425</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>24</Day></PubDate></JournalIssue><Title>Genes</Title><ISOAbbreviation>Genes (Basel)</ISOAbbreviation></Journal><ArticleTitle>Nonalcoholic Fatty Liver Disease in Patients with Inherited and Sporadic Motor Neuron Degeneration.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">936</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/genes13060936</ELocationID><Abstract><AbstractText>We describe evidence of fatty liver disease in patients with forms of motor neuron degeneration with both genetic and sporadic etiology compared to controls. A group of 13 patients with motor neuron disease underwent liver imaging and laboratory analysis. The cohort included five patients with hereditary spastic paraplegia, four with sporadic amyotrophic lateral sclerosis (ALS), three with familial ALS, and one with primary lateral sclerosis. A genetic mutation was reported in nine of the thirteen motor neuron disease (MND) patients. Fatty liver disease was detected in 10 of 13 (77%) MND patients via magnetic resonance spectroscopy, with an average dome intrahepatic triacylglycerol content of 17% (range 2-63%, reference &#x2264;5.5%). Liver ultrasound demonstrated evidence of fatty liver disease in 6 of the 13 (46%) patients, and serum liver function testing revealed significantly elevated alanine aminotransferase levels in MND patients compared to age-matched controls. Fatty liver disease may represent a non-neuronal clinical component of various forms of MND.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kokkinis</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gai</LastName><ForeName>Neville</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Radiology and Imaging Sciences, Clinical Center, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shamim</LastName><ForeName>Ejaz A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Mid-Atlantic Permanente Research Institute, Rockville, MD 20852, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blackstone</LastName><ForeName>Craig</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischbeck</LastName><ForeName>Kenneth H</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grunseich</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02124057</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>1ZIANS002974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Genes (Basel)</MedlineTA><NlmUniqueID>101551097</NlmUniqueID><ISSNLinking>2073-4425</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065626" MajorTopicYN="Y">Non-alcoholic Fatty Liver Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">fatty liver</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword><Keyword MajorTopicYN="N">steatosis</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>24</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35741698</ArticleId><ArticleId IdType="pmc">PMC9222520</ArticleId><ArticleId IdType="doi">10.3390/genes13060936</ArticleId><ArticleId IdType="pii">genes13060936</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kanning K.C., Kaplan A., Henderson C.E. Motor Neuron Diversity in Development and Disease. Annu. Rev. Neurosci. 2010;33:409&#x2013;440. doi: 10.1146/annurev.neuro.051508.135722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.051508.135722</ArticleId><ArticleId IdType="pubmed">20367447</ArticleId></ArticleIdList></Reference><Reference><Citation>Nodera H., Takamatsu N., Muguruma N., Ukimoto K., Nishio S., Oda M., Izumi Y., Kaji R. Frequent Hepatic Steatosis in Amyotrophic Lateral Sclerosis: Implication for Systemic Involvement. Neurol. Clin. Neurosci. 2015;3:58&#x2013;62. doi: 10.1111/ncn3.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ncn3.143</ArticleId></ArticleIdList></Reference><Reference><Citation>Deguise M.O., Baranello G., Mastella C., Beauvais A., Michaud J., Leone A., de Amicis R., Battezzati A., Dunham C., Selby K., et al. Abnormal Fatty Acid Metabolism Is a Core Component of Spinal Muscular Atrophy. Ann. Clin. Transl. Neurol. 2019;6:1519&#x2013;1532. doi: 10.1002/acn3.50855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.50855</ArticleId><ArticleId IdType="pmc">PMC6689695</ArticleId><ArticleId IdType="pubmed">31402618</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotter T.G., Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology. 2020;158:1851&#x2013;1864. doi: 10.1053/j.gastro.2020.01.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.01.052</ArticleId><ArticleId IdType="pubmed">32061595</ArticleId></ArticleIdList></Reference><Reference><Citation>Guber R.D., Takyar V., Kokkinis A., Fox D.A., Alao H., Kats I., Bakar D., Remaley A.T., Hewitt S.M., Kleiner D.E., et al. Nonalcoholic Fatty Liver Disease in Spinal and Bulbar Muscular Atrophy. Neurology. 2017;89:2481&#x2013;2490. doi: 10.1212/WNL.0000000000004748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004748</ArticleId><ArticleId IdType="pmc">PMC5729799</ArticleId><ArticleId IdType="pubmed">29142082</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo D., Kim R., Jung Y.J., Han K., Shin C.M., Lee J.-Y. Serum Gamma-Glutamyltransferase Activity and Parkinson&#x2019;s Disease Risk in Men and Women. Sci. Rep. 2020;10:1258. doi: 10.1038/s41598-020-58306-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-58306-x</ArticleId><ArticleId IdType="pmc">PMC6985223</ArticleId><ArticleId IdType="pubmed">31988422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunutsor S.K., Laukkanen J.A. Gamma Glutamyltransferase and Risk of Future Dementia in Middle-aged to Older Finnish Men: A New Prospective Cohort Study. Alzheimers Dement. 2016;12:931&#x2013;941. doi: 10.1016/j.jalz.2016.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.03.003</ArticleId><ArticleId IdType="pubmed">27103259</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson D., Finck B.N. Emerging Therapeutic Approaches for the Treatment of NAFLD and Type 2 Diabetes Mellitus. Nat. Rev. Endocrinol. 2021;17:484&#x2013;495. doi: 10.1038/s41574-021-00507-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-021-00507-z</ArticleId><ArticleId IdType="pmc">PMC8570106</ArticleId><ArticleId IdType="pubmed">34131333</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferramosca A., di Giacomo M., Zara V. Antioxidant Dietary Approach in Treatment of Fatty Liver: New Insights and Updates. World J. Gastroenterol. 2017;23:4146&#x2013;4157. doi: 10.3748/wjg.v23.i23.4146.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v23.i23.4146</ArticleId><ArticleId IdType="pmc">PMC5483489</ArticleId><ArticleId IdType="pubmed">28694655</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldink J.H., Kalmijn S., Groeneveld G.-J., Wunderink W., Koster A., de Vries J.H.M., van der Luyt J., Wokke J.H.J., van den Berg L.H. Intake of Polyunsaturated Fatty Acids and Vitamin E Reduces the Risk of Developing Amyotrophic Lateral Sclerosis. J. Neurol. Neurosurg. Psychiatry. 2007;78:367&#x2013;371. doi: 10.1136/jnnp.2005.083378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2005.083378</ArticleId><ArticleId IdType="pmc">PMC2077791</ArticleId><ArticleId IdType="pubmed">16648143</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrera-Juli&#xe1; S., Moreno M.L., Barrios C., de la Rubia Ort&#xed; J.E., Drehmer E. Antioxidant Alternatives in the Treatment of Amyotrophic Lateral Sclerosis: A Comprehensive Review. Front. Physiol. 2020;11:63. doi: 10.3389/fphys.2020.00063.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2020.00063</ArticleId><ArticleId IdType="pmc">PMC7016185</ArticleId><ArticleId IdType="pubmed">32116773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallsworth K., Thoma C., Moore S., Ploetz T., Anstee Q.M., Taylor R., Day C.P., Trenell M.I. Non-Alcoholic Fatty Liver Disease Is Associated with Higher Levels of Objectively Measured Sedentary Behaviour and Lower Levels of Physical Activity than Matched Healthy Controls. Frontline Gastroenterol. 2015;6:44&#x2013;51. doi: 10.1136/flgastro-2014-100432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/flgastro-2014-100432</ArticleId><ArticleId IdType="pmc">PMC4283712</ArticleId><ArticleId IdType="pubmed">25580206</ArticleId></ArticleIdList></Reference><Reference><Citation>Joo J.H., Kim H.J., Park E.C., Jang S.I. Association between Sitting Time and Non-Alcoholic Fatty Live Disease in South Korean Population: A Cross-Sectional Study. Lipids Health Dis. 2020;19:212. doi: 10.1186/s12944-020-01385-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12944-020-01385-6</ArticleId><ArticleId IdType="pmc">PMC7513533</ArticleId><ArticleId IdType="pubmed">32967678</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>